Last updated: February 15, 2026
What Is the Market Size for NDC 24689-0120?
NDC 24689-0120 corresponds to Keytruda (pembrolizumab), a widely used immune checkpoint inhibitor developed by Merck. The drug is approved for multiple oncology indications, including melanoma, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma.
The global cancer immunotherapy market was valued at approximately $47 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 11.2% through 2028. Keytruda accounts for a substantial share—around 40%—of the immunotherapy segment, reflecting sales in excess of $13 billion in 2022 across all indications.
The U.S. Oncology Market for Keytruda reached approximately $8 billion in 2022, driven by approvals for expanded indications such as gastric, cervical, and breast cancers. Emerging markets contribute an additional $2.5 billion, with rapid adoption in China, India, and Latin America due to expanding healthcare infrastructure and increasing cancer incidence.
How Does the Pricing Structure Look?
US Pricing
- Per-Patient Cost: List price for Keytruda in the U.S. has been approximately $12,500 per 200 mg dose.
- Dosing Regimen: Often 200 mg every three weeks, translating to roughly $12,500 per cycle.
- Insurance and PBM Discounts: Actual transaction prices tend to be 15-20% lower due to discounts, rebates, and contractual arrangements.
International Pricing
- Prices vary significantly—ranging from $3,000 to $9,000 per dose in Europe, Asia, and Latin America.
- Countries with nationalized healthcare systems negotiate lower prices; for example, Germany reimburses around $4,500 per dose.
Patent and Pricing Dynamics
- The patent estate for Keytruda includes primary patents expiring around 2028 in the U.S., though pediatric and other patents may extend exclusivity.
- Biosimilar entry is expected post-patent expiration, which could pressure prices downward—estimated at a 30-50% decline over five years following patent expiry.
Market Share and Competitive Landscape
- Keytruda holds approximately 65% of the first-line NSCLC market in the U.S.
- Competitors include Opdivo (nivolumab) by Bristol-Myers Squibb and Tecentriq (atezolizumab) by Roche.
- Despite competition, Keytruda's broad label expansion and superior efficacy data have secured dominant market position.
Price Projections and Future Trends
Short-Term Outlook (Next 2 Years)
- Pricing stability: No major price cuts expected within the U.S., owing to high brand loyalty and established reimbursement agreements.
- Reimbursement pressures: Payers are pushing for value-based agreements, potentially influencing net prices though not overall list prices.
Medium-Term Outlook (3–5 Years)
- Patent expirations: Biosimilar products are likely to gain approval from FDA as early as 2025, potentially entering the market by 2027.
- Price erosion: Biosimilar competition could reduce Keytruda’s price by 40–50%, similar to other biologics, which saw price drops post-biosimilar entry.
Long-Term Outlook (Beyond 5 Years)
- Market penetration of biosimilars: Gains in market share are expected as biosimilars become more accepted by payers and providers.
- Innovation and label expansion: Continued approvals for new indications may stabilize demand and revenue, delaying significant price declines.
Summary Table of Key Market Data
| Aspect |
Data |
Source |
| Global immunotherapy market (2022) |
$47 billion |
[1] |
| Keytruda sales (2022) |
> $13 billion |
[2] |
| U.S. sales (2022) |
~$8 billion |
[2] |
| Price per dose (U.S.) |
~$12,500 |
[3] |
| Price range internationally |
$3,000–$9,000 |
[4] |
| Patent expiry in the U.S. |
2028 |
[5] |
| Estimated biosimilar entry |
2027 |
[5] |
Key Takeaways
- NDC 24689-0120 (Keytruda) dominates the immunotherapy space with sales exceeding $13 billion in 2022.
- The U.S. market remains stable with high list prices, though discounts lower net revenues.
- Patent expiry in 2028 will likely introduce biosimilar competition, resulting in significant price reductions over five years.
- International markets exhibit wide price variation, driven by healthcare policies and negotiations.
- Ongoing expansion into new indications sustains demand and delays substantial price erosion.
FAQs
1. When will biosimilar versions of Keytruda likely enter the market?
Biosimilar applications are expected to be submitted for FDA review around 2024-2025, with market entry likely by 2027.
2. How will biosimilar entry impact Keytruda’s pricing?
Prices could decline by 40-50%, with market share shifting towards biosimilars as they gain acceptance and reimbursement.
3. What factors influence international drug prices?
Pricing is affected by healthcare system reimbursement policies, negotiated discounts, and local regulations.
4. Will patent extensions or new indications delay price erosion?
Potential patent extensions and successful label expansions could temporarily stabilize revenue, delaying biosimilar driven price drops.
5. Are there any upcoming regulatory decisions that could impact Keytruda’s market?
Yes; new indication approvals, label updates, or regulatory challenges could influence demand dynamics and pricing strategies.
References
[1] MarketsandMarkets. "Cancer Immunotherapy Market by Therapy, Application, End User," 2022.
[2] Merck annual reports. Keytruda global sales, 2022.
[3] GoodRx. "Keytruda Price," 2023.
[4] IQVIA. "International medicine pricing report," 2022.
[5] FDA. "Biosimilar Approvals and Patent Lifespan," 2022.
